Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Bonnet

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Neuropharmacology|March 1, 1996
In vivo striatal binding of the D1 antagonist SCH 23390 is not modified by changes in dopaminergic transmissionF Thibaut, J M Vaugeois, J J Bonnet, et al.
British Journal of Pharmacology|May 26, 2001
Involvement of the NH2 terminal domain of catecholamine transporters in the Na(2+) and Cl(-)-dependence of a [3H]-dopamine uptakeM Syringas, F Janin, B Giros, et al.
Annales Pharmaceutiques Francaises|August 18, 2004
[Assessment of the in vitro and in vivo toxicity of 3,4-dihydroxyphenylacetaldehyde (DOPAL)]J-J Bonnet, H Legros, Fr Janin, et al.
European Journal of Pharmacology|January 12, 1993
In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotionJ M Vaugeois, J J Bonnet, D Duterte-Boucher, et al.
Journal of Neurochemistry|January 14, 1999
Evidence for the sequential formation of two complexes between an uptake inhibitor, GBR 12783 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine], and the neuronal transporter of dopamineJ C Do-Régo, H Hue, J Costentin, et al.
Brain Research|June 15, 1999
Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in miceC Cleren, C Vilpoux, N Dourmap, et al.
Neuroscience Letters|July 17, 2009
Opiate receptors on mesolimbic dopaminergic neuronsH Pollard, C Llorens, J J Bonnet, et al.
British Journal of Pharmacology|September 28, 1999
Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the ratJ C Régo, M Syringas, B Leblond, et al.
Neuroscience Research|March 15, 2001
Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranesA Tidjane Corera, J C Do-Régo, J Costentin, et al.
Molecular Pharmacology|November 28, 2000
Structural domains of chimeric dopamine-noradrenaline human transporters involved in the Na(+)- and Cl(-)-dependence of dopamine transportM Syringas, F Janin, S Mezghanni, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Neuropharmacology|March 1, 1996
In vivo striatal binding of the D1 antagonist SCH 23390 is not modified by changes in dopaminergic transmissionF Thibaut, J M Vaugeois, J J Bonnet, et al.
British Journal of Pharmacology|May 26, 2001
Involvement of the NH2 terminal domain of catecholamine transporters in the Na(2+) and Cl(-)-dependence of a [3H]-dopamine uptakeM Syringas, F Janin, B Giros, et al.
Annales Pharmaceutiques Francaises|August 18, 2004
[Assessment of the in vitro and in vivo toxicity of 3,4-dihydroxyphenylacetaldehyde (DOPAL)]J-J Bonnet, H Legros, Fr Janin, et al.
European Journal of Pharmacology|January 12, 1993
In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotionJ M Vaugeois, J J Bonnet, D Duterte-Boucher, et al.
Journal of Neurochemistry|January 14, 1999
Evidence for the sequential formation of two complexes between an uptake inhibitor, GBR 12783 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine], and the neuronal transporter of dopamineJ C Do-Régo, H Hue, J Costentin, et al.
Brain Research|June 15, 1999
Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in miceC Cleren, C Vilpoux, N Dourmap, et al.
Neuroscience Letters|July 17, 2009
Opiate receptors on mesolimbic dopaminergic neuronsH Pollard, C Llorens, J J Bonnet, et al.
British Journal of Pharmacology|September 28, 1999
Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the ratJ C Régo, M Syringas, B Leblond, et al.
Neuroscience Research|March 15, 2001
Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranesA Tidjane Corera, J C Do-Régo, J Costentin, et al.
Molecular Pharmacology|November 28, 2000
Structural domains of chimeric dopamine-noradrenaline human transporters involved in the Na(+)- and Cl(-)-dependence of dopamine transportM Syringas, F Janin, S Mezghanni, et al.
Pageof 5